Regeneron Pharmaceuticals

Phone: +1 914-847-7000

Web: https://www.regeneron.com

Type	Public
Traded as	Nasdaq: REGN Nasdaq-100 component S&P 500 component
Industry	Pharmaceuticals; Biotech
Founded	1988 (1988)
Headquarters	Eastview/Tarrytown, New York, US (global headquarters)
Area served	Global
Key people	Leonard Schleifer (CEO) George Yancopoulos (CSO)
Revenue	US$8.497 billion (2020)
Net income	US$3.513 billion (2020)
Total assets	US$17.163 billion (2020)
Number of employees	9,123 (2020)
Website	www.regeneron.com

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, infectious diseases, pain and rare diseases. Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune® which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center®, which is conducting one of the largest genetics sequencing efforts in the world.

For detailed contact information visit location pages below.